Skip to content

Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder

Cognitive-Behavioral Treatment of Panic in Adolescence

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00705380
Enrollment
25
Registered
2008-06-26
Start date
1998-07-01
Completion date
2004-10-01
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Brief summary

This study will evaluate the effectiveness of cognitive behavioral therapy with a panic control treatment component in treating adolescents with panic disorder.

Detailed description

More than 3 million people in the United States will experience a panic attack at some point in their lives. A panic attack occurs when a person experiences an intense feeling of sudden fear as well as physical sensations of breathlessness, rapid heart beat, and dizziness. Panic disorder, which is characterized by reoccurring panic attacks, often develops during childhood or adolescence and, if left untreated, can interfere with a child's normal development, relationships, school work, and psychological well-being. Cognitive behavioral therapy (CBT) with a panic control treatment (PCT) component is a type of psychotherapy that teaches new ways to control anxiety or panic attacks. It has been found to be effective in treating adults with panic disorder. However, more research is needed to determine if CBT with PCT, when adapted specifically for adolescents, is also effective in treating adolescents with panic disorder. This study will evaluate the effectiveness of CBT with a PCT component in treating adolescents with panic disorder. Participation in this study will last up to 18 months. All participants will first undergo baseline assessments that will include a behavioral/psychological assessment while wearing a heart-rate monitoring device; questionnaires relating to experiences of anxiety, fear, and depression; and parent and child clinical interviews. Participants will then be assigned randomly to receive either immediate CBT with PCT or delayed CBT with PCT, which will occur after a 12-week waitlist period. CBT with PCT for all participants will include 11 weekly individual sessions, lasting 60 minutes each. During sessions, participants will learn specifically designed ways for adolescents to reduce or overcome panic attacks. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. During the 12-week waitlist period, the waitlist group participants will complete the same daily records and self-monitoring forms. The waitlist group participants will also meet with a therapist once every other week to discuss the nature of any panic attacks or address any concerns. Once all 12 weeks have passed, they will begin CBT with PCT. All participants will repeat the baseline assessments at Months 3, 6, and 12 after treatment.

Interventions

BEHAVIORALCognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents

CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.

BEHAVIORALWaitlist control

During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.

Sponsors

Boston University Charles River Campus
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Meets DSM-IV criteria for principal diagnosis of panic disorder or panic disorder with agoraphobia prior to treatment * If on medication, must undergo a 1-month stabilization period for benzodiazepines or 3-month stabilization period for selective serotonin reuptake inhibitors or tricyclics before study entry

Exclusion criteria

* Positive diagnosis of schizophrenia, pervasive developmental disorder, organic brain syndrome, or mental retardation * Current suicidal ideation * Refusal of parent to accept random assignment to treatment condition * Refusal of parent or adolescent to accept stabilization of medication

Design outcomes

Primary

MeasureTime frame
Anxiety Disorders Interview Schedule-Child and Parent Versions: Clinical Severity Rating, Agoraphobia Ratings, Weekly Panic Attack Frequency Scores, and Monthly Panic Attack Frequency ScoresMeasured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
Weekly Record of Anxiety and Depression (WRAD)Measured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
The Panic Attack Record (PAR)Measured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up

Secondary

MeasureTime frame
The Childhood Anxiety Sensitivity Index (CASI)Measured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
Children's Depression Inventory (CDI)Measured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
The Fear Survey Schedule for Children - RevisedMeasured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
The Revised Children's Manifest Anxiety ScaleMeasured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up
Behavioral Approach Test (BAT)Measured at pretreatment; post-treatment; and Months 3, 6, and 12 of follow-up

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSarah Mattis, PhD

Boston University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026